Results 31 to 40 of about 5,507 (191)
Hemicrania continua: a report of ten new cases [PDF]
Arquivos de Neuro-Psiquiatria, 2002 Hemicrania continua (HC) is an uncommon primary headache first described as a syndrome in 1984. Being quite unusual, its clinical characterization still demands better description.
Marcelo E. Bigal +3 more
doaj +1 more source
Efficacy of Symptomatic Treatment of Migraine
Pediatric Neurology Briefs, 2005 The evidence from randomized and clinical controlled trials concerning efficacy and tolerability of symptomatic treatment of migraine in children was reviewed by search of databases from inception to June 2004 at Erasmus Medical Centre, Rotterdam, and ...
J Gordon Millichap
doaj +1 more source
Polypharmacology guided drug repositioning approach for SARS-CoV2.
PLoS ONE, 2023 Drug repurposing has emerged as an important strategy and it has a great potential in identifying therapeutic applications for COVID-19. An extensive virtual screening of 4193 FDA approved drugs has been carried out against 24 proteins of SARS-CoV2 (NSP1-
Esther Jamir +5 more
doaj +1 more source
The Journal of Qazvin University of Medical Sciences, 2022 Background The acute respiratory syndrome named “COVID-19” is caused by a novel coronavirus called Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Hanifeh Shariatifar +3 more
doaj +1 more source
Ischemic Colitis Secondary to Ergotamine Use: A Case Study
Case Reports in Gastroenterology, 2011 A 48-year-old woman with a history of chronic migraines, initially admitted for inpatient management of intractable migraine headaches, developed new onset abdominal pain, hypotension, and diarrhea on hospital day number ten.
Regina E. Rodman +3 more
doaj +1 more source
Cerebral Venous Thrombosis with Migraine-Like Headache and the Trigeminovascular System
Case Reports in Neurological Medicine, 2016 Cerebral venous thrombosis- (CVT-) associated headache is considered a secondary headache, commonly presenting as intracranial hypertension headache in association with seizures and/or neurological signs. However, it can occasionally mimic migraine.
Fábio A. Nascimento +3 more
doaj +1 more source
The Journal of Headache and Pain, 2017 Background Dihydroergotamine (DHE) is an acute antimigraine agent that displays affinity for dopamine D2-like receptors, serotonin 5-HT1/2 receptors and α1/α2-adrenoceptors. Since activation of vascular α1/α2-adrenoceptors results in systemic vasopressor
Eduardo Rivera-Mancilla +6 more
doaj +1 more source
Frontiers in Pharmacology, 2022 The novel coronavirus disease (COVID-19) caused by SARS-CoV-2 virus spreads rapidly to become a global pandemic. Researchers have been working to develop specific drugs to treat COVID-19.
Xinbo Yang +3 more
doaj +1 more source
MedComm, Volume 7, Issue 2, February 2026.Neurons, immune cells, and other cellular components within the disease microenvironment (such as stromal cells and tumor cells) constitute a dynamically evolving ecosystem. Neurons directly modulate immune cell activity and inflammatory responses through the release of neurotransmitters (e.g., norepinephrine and CGRP), while also promoting tumor ...
Xin Guo +11 more
wiley +1 more source
Nano Select, Volume 7, Issue 1, January 2026.Nanoparticle‐driven nose‐to‐brain drug delivery offers a noninvasive approach to bypass the blood–brain barrier (BBB) and directly modulate reactive astrocytes in CNS disorders. This review highlights biodegradable nanoparticles for astrocyte modulation, enhancing drug bioavailability, sustained release, and neuroinflammation control.
Senamile M. Dlamini +3 more
wiley +1 more source